StocksRankings — AI Stock Picks & Rankings

AI Stock Picks — August 17, 2026

The 5 AI-selected stock picks for August 17, 2026 from StocksRankings — with full investment thesis, bull case, bear case, and key catalyst for each.

5 AI Stock Picks for August 17, 2026

  1. BX — Blackstone [Insider Buy]
    Blackstone is positioned to capture institutional capital flows as Q2 earnings growth rebounds and alternative asset allocations rise. The company’s $35.0M in net insider buying, combined with $4,425M in free cash flow and a 3.5% dividend, demonstrate both management conviction and strong financial flexibility. Its PEG ratio of 0.43 indicates attractive growth-adjusted value, especially as private market fundraising accelerates.
    Key risk: A sharp decline in private equity deal activity or asset valuations could compress fee income and slow fundraising momentum.
  2. CSGP — CoStar Group [Lowest PEG]
    CoStar Group operates the dominant digital real estate information platform, and the recent surge in Q2 corporate earnings growth supports further expansion in commercial property data demand. The company’s network effect is reinforced by 902% EPS growth and +202% FCF growth, which underpins its ability to reinvest in platform enhancements. The PEG ratio of 0.21 signals that the market is pricing CoStar’s growth at a steep discount, offering significant upside if execution continues.
    Key risk: A slowdown in commercial real estate transaction volumes could reduce demand for CoStar’s data services and pressure revenue growth.
  3. PFE — Pfizer [Lowest PEG]
    Pfizer stands to benefit from the Q2 corporate earnings surge, as its pipeline of specialty drugs and vaccines drives 310.4% EPS growth. The company’s $3.0M in recent insider buying and a forward P/E of 8.6x reflect management conviction and a low valuation relative to its growth. With a PEG ratio of 0.11, the stock is deeply discounted for its earnings trajectory, setting up a favorable risk-reward profile.
    Key risk: Unexpected regulatory setbacks or clinical trial failures could delay or reduce future drug approvals and revenue streams.

See today's picks · full picks history · AI pick track record